The SMART Clinic is involved with advancing medicine through clinical research trials.
YOUR SMART CLINIC MEDICAL DOCTORS ARE CURRENTLY RECRUITING FOR THE FOLLOWING RESEARCH STUDIES:
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Effectiveness of TG-C in Subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee
This is a research study for aged 40 and above males or females having moderate osteoarthritis knee pain. The study is evaluating a regenerative stem cell investigational product. The study drug (or placebo) will be administered via an injection into the painful knee. The study is being performed to determine if the study drug helps cartilage regenerate.
A Multicenter, Randomized, Double-blind, Sham-controlled, Comparative Study of SI-6603 in Subjects with Lumbar Disc Herniation (Phase 3)
This is a one yearlong study to evaluate if the study drug is more effective than placebo in reducing leg pain/leg pain symptoms caused by a herniated disc in the lumbar L4/L5 or L5/S1 vertebrae. Males and females aged 30 to 70 are encouraged to inquire about the study if they have had a L45 or L5/S1 disc herniation causing leg pain (radiculopathy) for less than one year.
Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (C.L.E.A.R.):
This is a double blind, placebo controlled study with open label injection option for individuals with single leg sciatica (radiculopathy) caused by a herniated disc protrusion or herniation in the Lumbar spine region. Leg pain symptoms need to have been present for at least six weeks and less than nine months. The study drug is Dexamethasone and a viscous vehicle. Subjects that qualify receive a transforaminal epidural injection. Leg pain is evaluated during study.
A Prospective, Randomized, Double-Blinded, Vehicle-and Placebo-Controlled, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of IDCT in Subjects with Single-Level, Symptomatic Lumbar Intervertebral Disc Degeneration.
The purpose of this study is to find out about the safety of IDCT and how IDCT affects lower back pain. The active ingredient in IDCT are live cells, known as Discogenic Cells. These cells, which are unique to this product, are made from donated spine tissue and modified in the lab to be therapeutic for degenerative disc disease.
A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Utilizing Patient Reported and Radiographic Outcomes to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects.
The objective of this study is to determine the effectiveness, safety, and tolerability of the investigation drug following injection into the one painful knee joint for the treatment of knee osteoarthritis (OA).
You do not need health insurance to participate. All studies provide no-cost medical and laboratory evaluations, MRI, X-ray or other imaging as applicable, and study compensation for time and travel is available.